Hypoglycemic and hypolipidemic effect of Allopolyherbal formulations in streptozotocin induced diabetes mellitus in rats

Abstract

In the present study, we examined and compared the effect of Polyherbal (PH), Allopolyherbal-A (APH-A), Allopolyherbal-B (APH-B), and Allopolyherbal-C (APH-C) formulations on hyperglycemia, lipid profile, renal, and hepatic function in streptozotocin (STZ) induced diabetes mellitus in rats. The hypoglycemic activity (along with other parameters) of Polyherbal and Allopolyherbal formulations was investigated in STZ induced diabetes in rats. Polyherbal (PH) (3.63 g/kg body wt.); Allopolyherbal-A (APH-A) [(5 mg Gliclazide + 1.81 g PH)/kg body wt.]; Allopolyherbal-B (APH-B) [(4 mg Gliclazide + 2.17 g of PH)/kg body wt.]; Allopolyherbal-C (APH-C) [(2 mg of Gliclazide + 2.904 g of PH)/kg body wt.], and Gliclazide (10 mg/kg body wt.) were administered once a day, orally by gavages for 21 days. Blood glucose levels were measured on 0, 7, 14, and 21 days of the study; total cholesterol, triglycerides, LDL, VLDL, HDL, serum creatinine, SGOT, and SGPT were estimated on 21st day. Gliclazide, Polyherbal (PH), Allopolyherbal-A (APH-A), Allopolyherbal-B (APH-B), and Allopolyherbal-C (APH-C) formulations treated rats showed significant (P < 0.01) decrease in blood glucose, total cholesterol, triglycerides, LDL, VLDL, serum creatinine, SGOT, and SGPT level, along with significant increase in HDL. Present findings provide experimental evidence that the combination of allopathic hypoglycemic drugs with hypoglycemic Polyherbal formulations provides effective and rapid glycemic control and can also minimize the cardiovascular risk factors of type II diabetes mellitus.